CLNP023B12302: A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN)06/13/2023 - 06/13/2027 (PI)
Novartis Pharma Corp
ALXN1210-TMA-315: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated with a Trigger.01/15/2022 - 01/14/2025 (PI)
Alexion Pharmaceuticals
Atypic Hemolytic Uremic Syndrome (aHUS)03/17/2017 - 03/17/2019 (PI)
Alexion Pharmaceuticals